definiens: ), Confidential Information ( as defined in Section 5.2 .1 ) and certain Existing INDs ( as defined in Sectio n 1.1.3 ) ; and WHEREAS, Aevi desires KKC to transfer to Aevi the r ecombinant CHOK1SV stable cell line expressing Anti - LIGHT mAb, which cell line is desig nated as ( * * * ) ( the ) ; and WHEREAS, Aevi has been using the Existing Clinical Materials, the Confidential Information, the Existing INDs and the Additional Antibody Mater ial ( as defined in Section 1.1.4 ) ( collectively, th e ) in connection with conducting the Adolescent Stu dy ( as defined in Section 2.3.1 ) ; and WHEREAS, Aevi desires to use the Materials and the Master Cell Line in connection with conducting the COVID Study ( as defined in Section 2 .4.1 ) ; and WHEREAS, Aevi desires to obtain exclusive options t o obtain licenses under certain intellectual property controlled by KKC to develop, manufacture and commercialize products containing Anti - LIGHT mAb ( ) in certain fields ; and -1- WHEREAS, KKC desires to allow Aevi to use the Mater ials solely as permitted under this Agreement and to grant such exclusive options to Ae vi, all under the terms and conditions of this Agre ement, which agreement amends and restates the Original CD OA